The goal of the partnership is to speed up the development of Cam Med’s Evopump – a conformable, disposable patch pump – so that the device can be integrated into closed-loop insulin delivery systems and cut back on the systems’ overall size.
“JDRF is excited to partner with Cam Med on improving insulin delivery hardware,” JDRF’s program scientist Jaime Giraldo said in prepared remarks. “The Evopump represents the type of miniaturized and user-centric design that could substantially reduce the burden of living with type 1 diabetes and remove obstacles preventing some people, particularly children, from using devices that could improve their glucose management.”
“The Evopump’s unique multi-reservoir, electrochemically-actuated design is a game-changer not just in terms of its user-friendly, bandage-like form, but also because it enables the Evopump to be manufactured at a much lower cost than conventional pumps,” Zhifei Ge, Cam Med’s CTO & co-inventor of the Evopump, added.
“This partnership with JDRF enables Cam Med to accelerate the development and commercialization of the Evopump, and we’re looking forward to it becoming the core delivery platform for future AP systems,” Cam Med CEO Larry Alberts said.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.